ARYx Therapeutics, Inc.
ARYXOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$16731
P/E Ratio—
52W High$0.00050000002
52W Low$0.000001
ARYx Therapeutics, Inc. (ARYX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ARYX · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2010Report Date: Nov 15, 2010EPS Actual
-$0.08
Est. -$0.09 · +11.1%
Revenue
—
Fiscal Period
Q4 FY2010
FY ends December
Report Date
Nov 15, 2010
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
ARYX reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q4 FY2010 | Nov 15, 2010 | -$0.09 | -$0.08 | +11.1% | — | — | — |
| ▼ Q3 FY2010 | Aug 16, 2010 | -$0.10 | -$0.11 | -10.0% | — | — | — |
| ▼ Q2 FY2010 | May 13, 2010 | -$0.16 | -$0.22 | -37.5% | — | — | — |
| ▲ Q1 FY2010 | Mar 29, 2010 | -$0.22 | -$0.21 | +4.5% | — | — | — |
| — Q4 FY2009 | Nov 12, 2009 | — | -$0.30 | — | — | — | — |
| ▼ Q3 FY2009 | Aug 13, 2009 | -$0.33 | -$0.34 | -3.0% | — | — | — |
| ▲ Q2 FY2009 | May 14, 2009 | -$0.49 | -$0.36 | +26.5% | — | — | — |
| — Q1 FY2009 | Mar 26, 2009 | -$0.57 | -$0.57 | +0.0% | — | — | — |
Q4 FY2010
Nov 15, 2010Beat
EPS Actual
-$0.08
EPS Est.
-$0.09
EPS Surpr.
+11.1%
Revenue
—
Q3 FY2010
Aug 16, 2010Miss
EPS Actual
-$0.11
EPS Est.
-$0.10
EPS Surpr.
-10.0%
Revenue
—
Q2 FY2010
May 13, 2010Miss
EPS Actual
-$0.22
EPS Est.
-$0.16
EPS Surpr.
-37.5%
Revenue
—
Q1 FY2010
Mar 29, 2010Beat
EPS Actual
-$0.21
EPS Est.
-$0.22
EPS Surpr.
+4.5%
Revenue
—
Q4 FY2009
Nov 12, 2009
EPS Actual
-$0.30
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2009
Aug 13, 2009Miss
EPS Actual
-$0.34
EPS Est.
-$0.33
EPS Surpr.
-3.0%
Revenue
—
Q2 FY2009
May 14, 2009Beat
EPS Actual
-$0.36
EPS Est.
-$0.49
EPS Surpr.
+26.5%
Revenue
—
Q1 FY2009
Mar 26, 2009
EPS Actual
-$0.57
EPS Est.
-$0.57
EPS Surpr.
+0.0%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2011 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2010 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2011 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2010 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2010 | Nov 15, 2010 | +11.1% | $0.42 | $0.41 | -1.90% |
| ▼ Q3 FY2010 | Aug 16, 2010 | -10.0% | $0.46 | $0.43 | -6.09% |
| ▼ Q2 FY2010 | May 13, 2010 | -37.5% | $0.76 | $0.75 | -1.83% |
| ▲ Q1 FY2010 | Mar 29, 2010 | +4.5% | $0.86 | $0.91 | +5.81% |
| — Q4 FY2009 | Nov 12, 2009 | — | $2.44 | $2.35 | -3.69% |
| ▼ Q3 FY2009 | Aug 13, 2009 | -3.0% | $3.55 | $3.67 | +3.38% |
| ▲ Q2 FY2009 | May 14, 2009 | +26.5% | $4.97 | $5.00 | +0.60% |
| ▲ Q1 FY2009 | Mar 26, 2009 | +0.0% | $3.50 | $3.52 | +0.57% |
Q4 FY2010-1.90%
Report Date
Nov 15, 2010
EPS Beat/Miss
+11.1%
Price Before
$0.42
Price After
$0.41
Q3 FY2010-6.09%
Report Date
Aug 16, 2010
EPS Beat/Miss
-10.0%
Price Before
$0.46
Price After
$0.43
Q2 FY2010-1.83%
Report Date
May 13, 2010
EPS Beat/Miss
-37.5%
Price Before
$0.76
Price After
$0.75
Q1 FY2010+5.81%
Report Date
Mar 29, 2010
EPS Beat/Miss
+4.5%
Price Before
$0.86
Price After
$0.91
Q4 FY2009-3.69%
Report Date
Nov 12, 2009
EPS Beat/Miss
—
Price Before
$2.44
Price After
$2.35
Q3 FY2009+3.38%
Report Date
Aug 13, 2009
EPS Beat/Miss
-3.0%
Price Before
$3.55
Price After
$3.67
Q2 FY2009+0.60%
Report Date
May 14, 2009
EPS Beat/Miss
+26.5%
Price Before
$4.97
Price After
$5.00
Q1 FY2009+0.57%
Report Date
Mar 26, 2009
EPS Beat/Miss
+0.0%
Price Before
$3.50
Price After
$3.52
Avg Beat Reaction+1.27%
Avg Miss Reaction-1.51%
Beat Rate4 / 8 quarters
Largest Move-6.09% (Q3 FY2010)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ARYX ends December
ARYx Therapeutics, Inc. (ARYX) most recently reported earnings on November 15, 2010 for Q4 FY2010, posting EPS of $-0.08 — beating the analyst consensus of $-0.09 by +11.1%. The next ARYX earnings date is expected around September 1, 2026.
Each quarter, investors track ARYX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ARYX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ARYX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ARYX earnings · 5 questionsARYx Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ARYX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ARYX historically reports after market close (AMC).
ARYX earnings datewhen is ARYX earningsARYX next earnings datewhen does ARYX report earningsARYX earnings calendar
▸ Source: FMP · ARYx Therapeutics, Inc. SEC filings · US GAAP · ARYx Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026